OmniAb (OABI) Intangibles (2021 - 2026)
OmniAb (OABI) reported Intangibles of $119.1 million for Q1 2026, down 11.65% year-over-year from $134.8 million in Q1 2025, and down 4.82% on a QoQ basis from $125.1 million in Q4 2025.
OmniAb (OABI) has 6 years of Intangibles data on file, last reported at $119.1 million in Q1 2026.
- Quarterly Intangibles fell 11.65% year-over-year to $119.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.1 million (down 11.65% YoY) and the FY2025 annual result came in at $125.1 million, down 9.35% from the prior year.
- Intangibles slipped to $119.1 million in Q1 2026 per OABI's latest filing, from $125.1 million in the prior quarter.
- Across five years, Intangibles topped out at $167.2 million in Q4 2022 and bottomed at $119.1 million in Q1 2026.
- The 5-year median for Intangibles is $145.8 million (2024), against an average of $144.9 million.
- The widest annual swing landed in 2022, when Intangibles retreated 5.15%; it then retreated 11.65% in 2026.
- Tracing OABI's Intangibles over 5 years: stood at $167.2 million in 2022, then dropped by 7.04% to $155.5 million in 2023, then dropped by 11.2% to $138.1 million in 2024, then retreated by 9.35% to $125.1 million in 2025, then fell by 4.82% to $119.1 million in 2026.
- Per Business Quant, the three latest OABI Intangibles figures stand at $119.1 million (Q1 2026), $125.1 million (Q4 2025), and $128.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.41 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 11,640.44 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 418.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.29 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 119.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119.12 Mn |
| Dec 31, 2025 | 125.15 Mn |
| Sep 30, 2025 | 128.38 Mn |
| Jun 30, 2025 | 131.61 Mn |
| Mar 31, 2025 | 134.83 Mn |
| Dec 31, 2024 | 138.06 Mn |
| Sep 30, 2024 | 144.12 Mn |
| Jun 30, 2024 | 147.51 Mn |
| Mar 31, 2024 | 152.06 Mn |
| Dec 31, 2023 | 155.47 Mn |
| Sep 30, 2023 | 158.77 Mn |
| Jun 30, 2023 | 161.92 Mn |
| Mar 31, 2023 | 164.36 Mn |
| Dec 31, 2022 | 167.24 Mn |
| Dec 31, 2021 | 176.32 Mn |